Ascendiant Capital Markets Forecasts GRI Bio Q2 Earnings

GRI Bio, Inc. (NASDAQ:GRI) – Research analysts at Ascendiant Capital Markets increased their Q2 2026 earnings per share estimates for shares of GRI Bio in a research report issued on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings per share of ($1.24) for the quarter, up from their prior estimate of ($1.55). Ascendiant Capital Markets has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($5.26) per share. Ascendiant Capital Markets also issued estimates for GRI Bio’s Q3 2026 earnings at ($1.21) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($5.13) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.22) EPS, Q3 2027 earnings at ($1.19) EPS, Q4 2027 earnings at ($1.16) EPS and FY2027 earnings at ($4.81) EPS.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.01).

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, GRI Bio currently has a consensus rating of “Hold” and an average target price of $32.00.

GRI Bio Stock Performance

Shares of GRI stock opened at $2.01 on Thursday. The stock’s fifty day moving average is $2.28 and its two-hundred day moving average is $10.41. The firm has a market capitalization of $3.56 million, a P/E ratio of -0.03 and a beta of -1.17. GRI Bio has a fifty-two week low of $1.97 and a fifty-two week high of $80.36.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.